An Educational Opportunity... ESMO2024 and the LEAP-012 trial!
How a colleague's well-intended comments prompted me to explain several common misunderstandings that should be better taught during oncology training.
Great comments. If the sample size was enlarged to 3 times of the current sample size, then the P value would be below 0.025 with a HR=0.80, therefore, the LEAP-012 study met its OS endpoint.
With these results, do you think its rationale to provide pts with len and pembro?
Unfortunately, not just oncology. Medicine and most of its drugs is delusional.
Great comments. If the sample size was enlarged to 3 times of the current sample size, then the P value would be below 0.025 with a HR=0.80, therefore, the LEAP-012 study met its OS endpoint.
With these results, do you think its rationale to provide pts with len and pembro?